# US 10,946,099 B2 · Compositions for photodynamic therapy and fluorescence diagnosis of cancers and other diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,946,099 B2 - Document ID: US10946099B2 - Status: Granted - Kind: B2 - Application number: 16/020,334 - Filed: 2018-06-27 - Published: 2019-02-21 - Granted: 2021-03-16 - Earliest claimed: 2017-06-27 - Assignees: Vision Global Holdings Ltd. - Applicants: Vision Global Holdings Limited - Inventors: Sui Yi Kwok; Norman Fung Man Wai; Terence Shau Yin Wai; Shan Yu - Web page: https://patentgrep.com/patent/US10946099B2 ## CPC - A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines} - A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to pharmaceutical compositions comprising a conjugate of a porphyrin (e.g., PpIX) and a recombinant protein. The pharmaceutical compositions of the invention may be used in photodynamic therapy. The invention also relates to methods of producing such pharmaceutical compositions and to methods of using such pharmaceutical compositions in the treatment of diseases, such as cancer. ## Claims ### Claim 1 A pharmaceutical composition for photodynamic therapy comprising an effective amount of at least one type of conjugate comprising a porphyrin, wherein the porphyrin is protoporphyrin IX (PpIX), and a recombinant protein comprising a di-alpha chain of human globin having the sequence set forth in SEQ ID NO:1 and two beta chains of human globin, each beta chain having the sequence set forth in SEQ ID NO:2, and a pharmaceutically acceptable excipient. ### Claim 2 (depends on 1) The pharmaceutical composition according to claim 1, wherein the recombinant proteins of human alpha and beta globin are is non-covalently associated with the porphyrin. ### Claim 3 (depends on 1) The pharmaceutical composition of claim 1, wherein a molar ratio of PpIX to the recombinant protein of human alpha and beta globin is in the range of 0.05 to 4. ### Claim 4 A method of treating cancer, the method comprising administering an effective amount of a pharmaceutical composition to an area of a patient in need of treatment, and irradiating the area in need of treatment to generate reactive oxygen species after administration of the pharmaceutical composition, thereby treating the cancer and wherein the pharmaceutical composition comprises an effective amount of at least one type of conjugate comprising a porphyrin, wherein the porphyrin is protoporphyrin IX (PpIX), and a recombinant protein comprising a di-alpha chain of human globin having the sequence set forth in SEQ ID NO:1 and two beta chains of human globin, each beta chain having the sequence set forth in SEQ ID NO:2, and a pharmaceutically acceptable excipient. ### Claim 5 (depends on 4) The method of claim 4, wherein the PpIX and the recombinant protein of human alpha and beta globin are non-covalently associated. ### Claim 6 (depends on 4) The method of claim 4, wherein the molar ratio of PpIX to the recombinant protein of human alpha and beta globin is in the range of 0.05 to 4. ### Claim 7 A method of producing a pharmaceutical composition, the method comprising constructing a vector plasmid comprising a promoter, a recombinant protein of human alpha and beta globin, and a selectable marker, transforming a bacterial strain by inserting the plasmid therein, wherein the bacterial strain endogenously produces PpIX; selecting bacterial clones using an antibiotic corresponding to the selectable marker; culturing the bacterial clones in a fermentation medium; purifying conjugates from the fermentation medium, wherein the conjugates comprise PpIX non-covalently associated with the recombinant protein of human alpha and beta globin; optionally adding a pharmaceutically acceptable carrier to the purified conjugates, thereby forming the pharmaceutical composition, and wherein the porphyrin is protoporphyrin IX (PpIX), wherein the recombinant protein comprises a di-alpha chain of human globin having the sequence set forth in SEQ ID NO:1 and two beta chains of human globin, each beta chain having the sequence set forth in SEQ ID NO:2. ### Claim 8 (depends on 7) The method of claim 7, wherein the bacterial strain is an E. coli strain selected from the group consisting of Jm109(DE3), clear coli and BL21 (DE3). ### Claim 9 (depends on 7) The method of claim 7, wherein the purified conjugates comprising PpIX and the recombinant protein of human alpha and beta globin are present at a molar ratio in the range of 0.05 to 4. ### Claim 10 A method of reducing the volume of a tumor in a subject, the method comprising: administering an effective amount of a pharmaceutical composition to an area of the subject where the tumor is found, wherein the pharmaceutical composition comprises at least one type of conjugate comprising a porphyrin and a recombinant protein of human alpha and beta globin; and wherein the porphyrin is protoporphyrin IX (PpIX), wherein the recombinant protein comprises a di-alpha chain of human globin having the sequence set forth in SEQ ID NO:1 and two beta chains of human globin, each beta chain having the sequence set forth in SEQ ID NO:2; a pharmaceutically acceptable excipient; and irradiating the area where the tumor is found to generate reactive oxygen species after administration of the pharmaceutical composition, thereby reducing the volume of the tumor in the area where of the subject where the tumor is found. ### Claim 11 (depends on 10) The method of claim 10, wherein the PpIX and the recombinant protein of human alpha and beta globin are non-covalently associated. ### Claim 12 (depends on 10) The method of claim 10, wherein the molar ratio of PpIX to the recombinant protein of human alpha and beta globin is in the range of 0.05 to 4. ### Claim 13 (depends on 10) The method of claim 10, wherein the conjugate is administered to the subject at a concentration of 200 to 400 mg/kg.